The DOI matches its Crossref record, with a small difference in title or year; 149 of the 150 references it cites were found in a registry or an index.
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
Open accessAbstract
Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary heart disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and treated early in childhood, individuals with FH can have normal life expectancy. This consensus paper aims to improve awareness of the need for early detection and management of FH children. Familial hypercholesterolaemia is diagnosed either on phenotypic criteria, i.e. an elevated low-density lipoprotein cholesterol (LDL-C) level plus a family history of elevated LDL-C, premature coronary artery disease and/or genetic diagnosis, or positive genetic testing. Childhood is the optimal period for discrimination between FH and non-FH using LDL-C screening. An LDL-C ≥5 mmol/L (190 mg/dL), or an LDL-C ≥4 mmol/L (160 mg/dL) with family history of premature CHD and/or high baseline cholesterol in one parent, make the phenotypic diagnosis. If a parent has a genetic defect, the LDL-C cut-off for the child is ≥3.5 mmol/L (130 mg/dL). We recommend cascade screening of families using a combined phenotypic and genotypic strategy. In children, testing is recommended from age 5 years, or earlier if homozygous FH is suspected. A healthy lifestyle and statin treatment (from age 8 to 10 years) are the cornerstones of management of heterozygous FH. Target LDL-C is <3.5 mmol/L (130 mg/dL) if >10 years, or ideally 50% reduction from baseline if 8-10 years, especially with very high LDL-C, elevated lipoprotein(a), a family history of premature CHD or other cardiovascular risk factors, balanced against the long-term risk of treatment side effects. Identifying FH early and optimally lowering LDL-C over the lifespan reduces cumulative LDL-C burden and offers health and socioeconomic benefits. To drive policy change for timely detection and management, we call for further studies in the young. Increased awareness, early identification, and optimal treatment from childhood are critical to adding decades of healthy life for children and adolescents with FH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Monogenic disorders such as familial hypercholesterolemia (FH) can be easily recognized from the standard lipid panel without the need to measure apoB [31,32].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a pediatric setting, reporting age-and gender-specific reference intervals is relevant for early identification of children with hyperlipidemia associated with premature atherosclerosis, especially FH [32].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredIn the citing paper
“Volanesorsen reduced plasma TGs by ∼70% and ApoC-III by 80-90% [349].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [349]
In the citing paper
“Although placebo-controlled trials are missing in children, there are observational studies suggesting that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate development of atherosclerosis and improve coronary outcomes. 303”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [303]
In the citing paper
“FH is diagnosed in children based on phenotypic criteria including elevated LDL-C plus a family history of elevated LDL-C, premature CAD and/or positive genetic testing. 303”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [303]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Berenson, G. S., Srinivasan, S. R., Bao, W., Newman, W. P., Tracy, R. E., & Wattigney, W. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806043382302 · Cited by 4,032
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Self-citationPrinciples and Practice of Screening for Disease.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-5-1085_2 · Cited by 3,066
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Self-citationSystematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Role of Oxidative Modifications in Atherosclerosis
Stocker, R., & Keaney, J. F. (2004) · Physiological Reviews · doi:10.1152/physrev.00047.2003 · Cited by 2,624 · cited 1×
“then accumulate in the artery wall, become oxidatively modified, and subsequently initiate an inflammatory response, which results in vascular injury and formation of atherosclerotic plaque.(25,26) Additional alterations in the lipoproteinprofile in FHmay involveelevated”
BackgroundLipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Self-citationAllhoff, P., Laaser, U., & Heinrich, J. (1991) · Kompendium der Lipid-Studien · doi:10.1007/978-3-642-95642-3_7 · Cited by 1,329
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citation
Research works printed but not linked: 3
- Central Intelligence Agency, The World Factbook 2014
- National Health, Lung, and Blood Institute, Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents
- Nherera, Saving Lives, Saving Families: The Health, Social and Economic Advantages of Detecting and Treating Familial Hypercholesterolaemia (FH)
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Self-citationFerence, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationPadmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
“3 Familial hypercholesterolaemia in children FH is diagnosed in children based on phenotypic criteria including elevated LDL-C plus a family history of elevated LDL-C, premature CAD and/or positive genetic testing.(303) Testing during childhood is optimal to discriminate between FH and non-FH using LDL-C.”
BackgroundSelf-citation
Metadata
- Authors
- Wiegman, A., Gidding, S. S., Watts, G. F., Chapman, M. J., Ginsberg, H. N., Cuchel, M., Ose, L., Averna, M., Boileau, C., Borén, J., Bruckert, E., Catapano, A. L., Defesche, J. C., Descamps, O. S., Hegele, R. A., Hovingh, G. K., Humphries, S. E., Kovanen, P. T., Kuivenhoven, J. A., Masana, L., Nordestgaard, B. G., Pajukanta, P., Parhofer, K. G., Raal, F. J., Ray, K. K., Santos, R. D., Stalenhoef, A. F. H., Steinhagen- Thiessen, E., Stroes, E. S., Taskinen, M.-R., Tybjærg-Hansen, A., & Wiklund, O.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Alfred I. duPont Hospital for Children (US)
- The University of Western Australia (AU)
- Inserm (FR)
- Columbia University Irving Medical Center (US)
- University of Pennsylvania (US)
- Oslo University Hospital (NO)
- University of Palermo (IT)
- University of Gothenburg (SE)
- University of Milan (IT)
- Hôpital de Jolimont (BE)
- Western University (CA)
- University of London (GB)
- Wihuri Research Institute (FI)
- University Medical Center Groningen (NL)
- Universitat Rovira i Virgili (ES)
- University of Copenhagen (DK)
- University of California, Los Angeles (US)
- Ludwig-Maximilians-Universität München (DE)
- University of the Witwatersrand (ZA)
- Imperial College London (GB)
- Universidade de São Paulo (BR)
- Radboud University Medical Center (NL)
- University of Helsinki (FI)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Wiegman, Albert
- ORCID
- Wiegman, Albert
- Gidding, Samuel S.
- Watts, Gerald F.
- Chapman, M. John
- Ginsberg, Henry N.
- Cuchel, Marina
- Averna, Maurizio
- Borén, Jan
- Catapano, Alberico L.
- Defesche, Joep C.
- Descamps, Olivier S.
- Hegele, Robert A.
- Hovingh, G. Kees
- Humphries, Steve E.
- Kovanen, Petri T.
- Kuivenhoven, Jan Albert
- Masana, Luis
- Nordestgaard, Børge G.
- Pajukanta, Päivi
- Parhofer, Klaus G.
- Raal, Frederick J.
- Ray, Kausik K.
- Santos, Raul D.
- Stroes, Erik S.
- Taskinen, Marja-Riitta
- Wiklund, Olov
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-25
- Volume
- 36
- Issue
- 36
- Pages
- 2425-2437
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC4576143
- OpenAlex
- W2104299102
- Cited by
- 891
- References
- 150
- Citations by year
- 2026: 79 · 2025: 80 · 2024: 74 · 2023: 87 · 2022: 99 · 2021: 77 · 2020: 80 · 2019: 60 · 2018: 89 · 2017: 77 · 2016: 68 · 2015: 21
- FWCI
- 85.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Heart Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- UWA Profiles and Research Repository (UWA) (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- Rovira & Virgili repository (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Työväentutkimus Vuosikirja (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Amgen, Aegerion, AstraZeneca, Genzyme, Hoffman-La Roche, Kowa Europe, Novartis, and Sanofi-Aventis/Regeneron
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- familial hypercholesterolemia, children and adolescents, family screening, phenotypic diagnosis, genetic testing, statin therapy, LDL cholesterol targets, premature coronary artery disease, life expectancy, cardiovascular risk, heterozygous familial hypercholesterolemia, lipoprotein(a)
- MeSH terms
- Adolescent, Adult, Child, Counseling, Diet, Economics, Medical, Female, Genetic Testing, Heterozygote, Homozygote, Humans, Hyperlipoproteinemia Type II, Life Expectancy, Middle Aged, Pregnancy, Pregnancy Complications, Risk Factors, Cost of Illness, Evidence-Based Medicine, Clinical Laboratory Techniques, Dietary Supplements, Early Diagnosis, Atherosclerosis, Medication Adherence, Young Adult, Carotid Intima-Media Thickness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. https://app.cochat.ai/papers/10.1093/eurheartj/ehv157
- The paper
- Wiegman, A., Gidding, S. S., Watts, G. F., Chapman, M. J., Ginsberg, H. N., Cuchel, M., Ose, L., Averna, M., Boileau, C., Borén, J., Bruckert, E., Catapano, A. L., Defesche, J. C., Descamps, O. S., Hegele, R. A., Hovingh, G. K., Humphries, S. E., Kovanen, P. T., Kuivenhoven, J. A., . . . Wiklund, O. (2015). Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv157
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.